Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Palbociclib in Dedifferentiated Liposarcoma: NCT06843967 Clinical Landscape Report 2026
15 October 2026
NCT06843967 clinical landscape for Dedifferentiated Liposarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanubrutinib in Diffuse Large B-Cell Lymphoma: NCT06846463 Clinical Landscape Report 2026
15 October 2026
NCT06846463 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Advanced Triple-Negative Breast Carcinoma: NCT06849492 Clinical Landscape Report 2026
15 October 2026
NCT06849492 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Umbilical Cord Blood Natural Killer Cell Therapy(Sun Yat-sen University) in Refractory Soft Tissue Sarcoma: NCT06848582 Clinical Landscape Report 2026
15 October 2026
NCT06848582 clinical landscape for Refractory Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[18F]RCCB6 in Mantle-Cell Lymphoma: NCT06852638 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_03_d2c7dad0d6.jpg)
9 min read
[18F]RCCB6 in Mantle-Cell Lymphoma: NCT06852638 Clinical Landscape Report 2026
15 October 2026
NCT06852638 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ZM001 in Systemic Lupus Erythematosus: NCT06852573 Clinical Landscape Report 2026
15 October 2026
NCT06852573 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQB-2825 in Diffuse Large B-Cell Lymphoma: NCT06854445 Clinical Landscape Report 2026
15 October 2026
NCT06854445 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Breast Cancer: NCT06856499 Clinical Landscape Report 2026
15 October 2026
NCT06856499 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Odronextamab in Diffuse large B-cell lymphoma refractory: NCT06854159 Clinical Landscape Report 2026
15 October 2026
NCT06854159 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
TQB3702 in Systemic Lupus Erythematosus: NCT06859931 Clinical Landscape Report 2026
15 October 2026
NCT06859931 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sonrotoclax in Refractory Grade 3a Follicular Lymphoma: NCT06859008 Clinical Landscape Report 2026
15 October 2026
NCT06859008 clinical landscape for Refractory Grade 3a Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
GNC-038 in Systemic Lupus Erythematosus: NCT06857214 Clinical Landscape Report 2026
15 October 2026
NCT06857214 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.